PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ZEV Begins Delivery of the ZEV 5000 High Performance, Low Priced, Electric Motor Scooter

ZEV (Z Electric Vehicle) has begun deliveries on its new ZEV5000 - a high performance electric motor scooter for the commuter rider designed around significant advances in NON exotic, lead based battery. 62 mph, 50 mile range, for $4500.

ZEV Begins Delivery of the ZEV 5000 High Performance, Low Priced, Electric Motor Scooter
2012-06-08
MORGANTOWN, WV, June 08, 2012 (Press-News.org) The launch of the 5000 LA might seem a bit in conflict with the ZEV image of high performance. ZEV is mostly known for its high tech, 100 mile (160 km) range / 75 - 80 mph (120 - 130 kmh) speed lithium battery powered bikes. Equally, the public has seemed to keep its focus on new and exotic battery technology. But for the vast majority of the population, their needs and use patterns could best be served by a new approach, rather than a new technology. The vast majority of the public needs a vehicle to commute to work less than 20 miles. The achieved goal of the new 5000 LA for ZEV engineers was to keep the speed up to over 62 mph /100 Kmh while exceeding that general public need with a range of 50 miles / 80 km in open roads, and 25 miles / 40 km in heavy traffic while reducing the weight of the vehicle and its cost. With the world economy not exactly booming, the intent was to try to create the maximum value product for the market and to drive down the sale price. The electric ZEV already have won following for their near zero maintenance cost. Driving the purchase price down was the intent of the 5000.

By using new advances in lead battery technology that has seen battery capacity jump over 11.2% in the last year, ZEV was able to create an electric motor scooter with a top speed of 62 mph /100 Kmh and a range of 50 miles / 80 km in open roads, and 25 miles / 40 km in heavy traffic at a $4545 USD MSRP (a price far less than equivalent speed lithium battery powered bikes). In comparison to equal priced lithium battery bikes produced by other manufacturers, the buyer gets 40% more range for the same money and gets about 19% more speed in the bargain.

While the news has been full of stories of new technology in exotic battery, the technology of the lead battery has steadily progressed also. ZEV was able to gain 11.2% in kwh capacity in the lead battery in just the last year and a similar decrease in weight while the cost went down slightly per battery, regardless of the kwh capacity. The historical lead battery problem of plate sulphating based on the use of sulphuric acid does not exist with these new batteries as the normal acid is replaced with an electrolyte of a liquid low sodium silicate compound. Additionally, the non acid lead battery can have a quicker recharge time rivaling on the street lithium bikes and low temperature performance does not suffer.

The ZEV5000 uses a 72 volt nominal (84 volt peak) system with a capacity of 3.36 kwh. The cost of this is $600 compared to $1750 for a ZEV equivalent lithium system (or $5000 in some brands of electric bike). The BMS system for the lithium battery is also not needed for the lead battery and assembly times fall with the easier installation further reducing costs. As these cost savings are always multiplied by dealer margins, the savings are significant when not one bit of performance is lost. The $600 cost of a full battery pack is also a factor when the time comes for a customer to eventually replace their battery.

The primary market target was the 4000 watt lithium motor scooters on the market around the world. ZEV wanted more range, more speed, and a lower price compared to the competition. This design effort was made to dovetail with an entire model line chassis redesign to create a modular chassis system where all of the variants used simple bolt on battery boxes to adjust for capacity and power. This chassis system change in term was done to eliminate multiple certification efforts such that only one test of the heaviest and fastest variant could be tested by the country government testing body, and the lighter/slower variants would fall under the first bike test results. This again cut vehicle costs so that the new bike could be offered at the same $4,545 MSRP USD price as its three year old predecessor.

At 40 Ah/battery, the new lead batteries are the equal Ah to the competitions lithium battery but at a heavier weight. The decision was made to just use more lead battery than the count of lithium battery that the competitors used for their lithium bikes. The results using the new high capacity lead battery was a 3.36 kwh capacity bike vs the competitions lithium 2.4 kwh. The extra battery raised the ZEV speed15% over its lithium competitor with a 37% range advantage, and only a 31 lb weight disadvantage, while enabling lowering of the price under all similar performance comparisons. By lowering the battery box slightly, the balance of the lead battery bike was made to equal the lighter lithium bike.

The lead battery offers extreme recycle ability for the greenest options. Lead batteries are constantly recycled and the new battery can go right into existing recycle programs. Lead battery systems also seem to have appeal to riders/owners who maintain their own bikes. Without the BMS system of a lithium bike, the lead battery bike is a quick and easy change out when the time comes for even a novice mechanic.

The new 5000 model shares the newest and latest ZEV hub motor design with other vehicles in the company line up. With the ability to take continuous power to 8,000 watts and launch power to 16,000 watts, the motor contributes heavily toward the range and efficiency of the new 5000 as does the 3 speed "electronic transmission" controller used by ZEV.

ZEV is a electric motor cycle and scooter company. We make the world's fastest and longest range electric two and three wheel vehicles. For more information on the ZEV 5000 (or the ZEV lithium powered bikes, visit www.zelectricvehicle.com or contact sales@ZElectricVehicle.com or phone 1-304-291-3843 (USA).

[Attachments] See images for this press release:
ZEV Begins Delivery of the ZEV 5000 High Performance, Low Priced, Electric Motor Scooter ZEV Begins Delivery of the ZEV 5000 High Performance, Low Priced, Electric Motor Scooter 2 ZEV Begins Delivery of the ZEV 5000 High Performance, Low Priced, Electric Motor Scooter 3

ELSE PRESS RELEASES FROM THIS DATE:

Scientists find that rain may not always be a welcome thing to waterbirds

2012-06-08
Scientists from the Smithsonian and colleagues have found that waterbird communities can be the "canary in the coal mine" when it comes to detecting the health of urban estuary ecosystems. Their research revealed that the types of waterbirds that inhabit urban estuaries are influenced not only by urban development, but also by a far more natural process―rain. The team's findings are published in the scientific journal PLoS ONE. The scientists compared waterbird communities in estuaries of the Chesapeake Bay during 2002, a year of severe drought, to 2003, a year ...

Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR

2012-06-08
PHILADELPHIA — For nearly 50 years, the American Heart Association, with the help of researchers and physicians from across the nation, has developed and disseminated guidelines on how best to perform cardiopulmonary resuscitation on patients experiencing cardiac arrest. But no such evidence-based guidelines existed in the veterinary world. Perhaps as a result, while more than 20 percent of human patients who suffer cardiac arrests in the hospital survive to go home to their families, the equivalent figure for dogs and cats is less than 6 percent. Now the Reassessment ...

76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12

2012-06-08
Berlin, Germany, June 8 2012: Data from a Phase IIb study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, show that 76% of patients with active rheumatoid arthritis (RA) receiving either 4mg or 8mg of baricitinib, an oral JAK1/JAK2 inhibitor, plus stable methotrexate (MTX) achieved ACR20* response compared with 41% of placebo-treated patients (p≤0.001) at 12 weeks. The 4mg and 8mg doses of baricitinib demonstrated statistical superiority to placebo in all clinical outcomes measured, including ACR20/50/70*, DAS28**-CRP ...

Novel brain imaging technique explains why concussions affect people differently

2012-06-08
June 8, 2012 — (Bronx, NY) — Patients vary widely in their response to concussion, but scientists haven't understood why. Now, using a new technique for analyzing data from brain imaging studies, researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that concussion victims have unique spatial patterns of brain abnormalities that change over time. The new technique could eventually help in assessing concussion patients, predicting which head injuries are likely to have long-lasting neurological consequences, ...

Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis

2012-06-08
Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs. This American study, the largest of its kind, followed 2,811 treatment naïve patients initiated onto anti-TNF therapy. Of the study group, 19% (n=521) were smokers and 81% (n=2,290) were non-smokers. Smokers had significantly higher scores on the Clinical Disease ...

Lung changes are present in nearly half of ACPA positive RA patients at disease onset

2012-06-08
Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA). Study findings show that 51% of RA patients (n=105) had identifiable lung changes (as measured by high resolution computer tomography [HRCT]) as compared to 28% of healthy controls (n=43). In addition, ACPA presence – but not smoking status – was associated with HRCT changes. This ...

Obesity negatively predicts minimal disease activity achievement in patients with PSA

2012-06-08
Berlin, Germany, June 8 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet. The results of an Italian study of 138 obese PsA patients demonstrated that those who achieved a ≥10% weight ...

Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo

2012-06-08
Berlin, Germany, June 8 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo. Significant improvements were also seen with UST 45mg and 90mg in ACR50* (24.9% ...

Early menopause predicts a milder form of rheumatoid arthritis

2012-06-08
Berlin, Germany, June 8 2012 : A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA). New insights on factors influencing RA are good news for sufferers of the chronic inflammatory disease that currently affects over 2 million women in Europe. 1,2 The study, based on 134 incident RA cases, found that patients aged over 45 years with a history of early menopause were 50% less likely to develop severe RA (16% versus 35%) and more likely to develop ...

Rabbit risk score can help rheumatologists identify patients at high risk of infection

2012-06-08
Berlin, Germany, June 8 2012: Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients with rheumatoid arthritis (RA) who are treated with anti-tumour necrosis factor drugs (anti-TNFs) or conventional disease modifying anti-rheumatic drugs (DMARDs) is a valid and effective tool for rheumatologists to predict risk of serious infection. The German study used data from 2,603 patients enrolled in the RABBIT ...

LAST 30 PRESS RELEASES:

SwRI-built instruments to monitor, provide advanced warning of space weather events

Breakthrough advances sodium-based battery design

New targeted radiation therapy shows near-complete response in rare sarcoma patients

Does physical frailty contribute to dementia?

Soccer headers and brain health: Study finds changes within folds of the brain

Decoding plants’ language of light

UNC Greensboro study finds ticks carrying Lyme disease moving into western NC

New implant restores blood pressure balance after spinal cord injury

New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows

Could a local anesthetic that doesn’t impair motor function be within reach?

1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5

In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day

Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds

Bronze and Iron Age cultures in the Middle East were committed to wine production

Indian adolescents are mostly starting their periods at an earlier age than 25 years ago

Temporary medical centers in Gaza known as "Medical Points" (MPs) treat an average of 117 people daily with only about 7 staff per MP

Rates of alcohol-induced deaths among the general population nearly doubled from 1999 to 2024

PLOS One study: In adolescent lab animals exposed to cocaine, High-Intensity Interval Training boosts aversion to the drug

Scientists identify four ways our bodies respond to COVID-19 vaccines

Stronger together: A new fusion protein boosts cancer immunotherapy

Hidden brain waves as triggers for post-seizure wandering

Music training can help the brain focus

Researcher develop the first hydride ion prototype battery

MIT researchers find a more precise way to edit the genome

‘Teen’ pachycephalosaur butts into fossil record

Study finds cocoa extract supplement reduced key marker of inflammation and aging

Obesity treatment with bariatric surgery vs GLP-1 receptor agonists

Nicotinamide for skin cancer chemoprevention

Novel way to ‘rev up’ brown fat burns calories, limits obesity in mice

USC Stem Cell-led team makes major advance toward building a synthetic kidney

[Press-News.org] ZEV Begins Delivery of the ZEV 5000 High Performance, Low Priced, Electric Motor Scooter
ZEV (Z Electric Vehicle) has begun deliveries on its new ZEV5000 - a high performance electric motor scooter for the commuter rider designed around significant advances in NON exotic, lead based battery. 62 mph, 50 mile range, for $4500.